Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Boundless Bio, Inc.BOLD · Entity 7063 | Chief Medical Officer | January 23, 2026 | January 26, 2026 |
| Rain Oncology Inc.RAIN · Entity 94695 | See Remarks | January 26, 2024 | January 26, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Boundless Bio, Inc.
Report date January 23, 2026 · Filed January 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2036-01-22 | Direct | 230,000 |
Reported balance
After 2026-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-23 · Grant · Acquired 230,000 · Balance 230,000 F1: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter.
Rain Oncology Inc.
Report date January 26, 2024 · Filed January 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 1
1 source rowRow 1 · 2024-01-26 · Other · Disposed 476,827 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.59 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-26 · Disposition to issuer · Disposed 11,119 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-26 · Disposition to issuer · Disposed 90,620 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.01 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-26 · Disposition to issuer · Disposed 12,358 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-01-26 · Disposition to issuer · Disposed 5,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-01-26 · Disposition to issuer · Disposed 13,890 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.59 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-01-26 · Disposition to issuer · Disposed 112,206 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-01-26 · Disposition to issuer · Disposed 9,260 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-01-26 · Disposition to issuer · Disposed 99,400 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-01-26 · Disposition to issuer · Disposed 49,700 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-01-26 · Disposition to issuer · Disposed 9,260 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-01-26 · Disposition to issuer · Disposed 1,981 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.01 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2024-01-26 · Disposition to issuer · Disposed 59,642 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right.
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2026 Filed Jan 26, 2026 12:00 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option (right to buy) · Derivative | 230,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001193125-26-021656 · ownership.xml · derivative · entry 1 Doebele Robert · CIK 0001856681 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2036-01-22 F1 · derivative.exercise_date: The vesting commencement date is January 1, 2026. The stock option vests in 48 substantially equal monthly installments. Accordingly, 1/48th of this stock option vests on February 1, 2026, and monthly thereafter. Read SEC document |
| February 03, 2025 Filed Feb 3, 2025 23:38 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | GrantStock Option · Derivative | 180,000 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0000950170-25-012568 · ownership.xml · derivative · entry 1 Doebele Robert · CIK 0001856681 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The option shall vest over a period of four years, with 25% of the shares subject to the option vesting on February 3, 2026, and the remaining shares subject to the option vesting in 36 equal monthly installments thereafter, subject to continued employment or service to the issuer on each such vesting date. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:36 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 59,642 | Not disclosed Strike: $12.01 | Not disclosed |
DisclosureSEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 13 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,642 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:36 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,981 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 12 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,981 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:36 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,260 | Not disclosed Strike: $3.13 | Not disclosed |
DisclosureSEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 11 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,260 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:36 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 49,700 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 10 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,700 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:36 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 99,400 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 9 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 99,400 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:36 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,260 | Not disclosed Strike: $3.95 | Not disclosed |
DisclosureSEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 8 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,260 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:36 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 112,206 | Not disclosed Strike: $9.59 | Not disclosed |
DisclosureSEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 7 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 112,206 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:36 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,890 | Not disclosed Strike: $3.95 | Not disclosed |
DisclosureSEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 6 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,890 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:36 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 5,000 | Not disclosed Strike: $3.95 | Not disclosed |
DisclosureSEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 5 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:36 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,358 | Not disclosed Strike: $12.01 | Not disclosed |
DisclosureSEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 4 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,358 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:36 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 90,620 | Not disclosed Strike: $4.00 | Not disclosed |
DisclosureSEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 3 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,620 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:36 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,119 | Not disclosed Strike: $9.59 | Not disclosed |
DisclosureSEC source: 0001999371-24-000958 · ownership.xml · derivative · entry 2 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,119 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:36 UTC | Rain Oncology Inc. RAIN · Entity 94695 | OtherCommon Stock, par value $0.001 per share | 476,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001999371-24-000958 · ownership.xml · nonDerivative · entry 1 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. F1 · acquired: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 21:16 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 49,700 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001104659-23-090705 · tm2323614-9_4seq1.xml · derivative · entry 2 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,700 Underlying: Common Stock · 49,700 shares Expires 2033-08-09 F2 · derivative.exercise_date: This option represents a right to purchase a total of 49,700 shares of the Issuer's common stock, which will vest in equal installments on May 9, 2024 and February 9, 2025, subject to the achievement of certain corporate goals and the Reporting Person's continued service to the Issuer. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 21:16 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 99,400 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001104659-23-090705 · tm2323614-9_4seq1.xml · derivative · entry 1 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,400 Underlying: Common Stock · 99,400 shares Expires 2033-08-09 F1 · derivative.exercise_date: This option represents a right to purchase a total of 99,400 shares of the Issuer's common stock, which will vest in equal installments on May 9, 2024 and February 9, 2025, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 18:18 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 123,325 | $0.00 Strike: $9.30 | $0.00 |
DisclosureSEC source: 0001104659-23-023387 · tm237300-2_4seq1.xml · derivative · entry 1 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,325 Underlying: Common Stock · 123,325 shares Expires 2033-02-15 F1 · derivative.exercise_date: This option represents a right to purchase a total of 123,325 shares of the Issuer's common stock, one quarter of which will vest on February 15, 2024, with the remaining three quarters vesting in equal monthly installments through February 15, 2027, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 06, 2022 Filed Jul 7, 2022 18:02 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,890 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0000899243-22-025741 · doc4.xml · derivative · entry 2 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 3,890 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents a right to purchase a total of 13,890 shares of Issuer's common stock, which is vested in full. Read SEC document |
| July 06, 2022 Filed Jul 7, 2022 18:02 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Exercise / conversionCommon Stock | 3,890 | $3.95 | $15,365.50 |
DisclosureSEC source: 0000899243-22-025741 · doc4.xml · nonDerivative · entry 1 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 16:30 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0000899243-22-014886 · doc4.xml · derivative · entry 2 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,890 Underlying: Common Stock · 3,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents a right to purchase a total of 13,890 shares of Issuer's common stock, which is vested in full. Read SEC document |
| April 13, 2022 Filed Apr 15, 2022 16:30 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Exercise / conversionCommon Stock | 3,000 | $3.95 | $11,850.00 |
DisclosureSEC source: 0000899243-22-014886 · doc4.xml · nonDerivative · entry 1 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 16:15 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $3.95 | $0.00 |
DisclosureSEC source: 0000899243-22-013322 · doc4.xml · derivative · entry 2 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,890 Underlying: Common Stock · 2,000 shares Expires 2029-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option represents a right to purchase a total of 13,890 shares of Issuer's common stock, which is vested in full. Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 16:15 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Exercise / conversionCommon Stock | 2,000 | $3.95 | $7,900.00 |
DisclosureSEC source: 0000899243-22-013322 · doc4.xml · nonDerivative · entry 1 Doebele Robert · CIK 0001856681 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2022 Filed Feb 4, 2022 16:35 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 72,000 | $0.00 Strike: $12.01 | $0.00 |
DisclosureSEC source: 0000899243-22-004834 · doc4.xml · derivative · entry 1 Doebele Robert · CIK 0001856681 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2032-01-07 F1 · derivative.exercise_date: This option represents a right to purchase a total of 72,000 shares of the Issuer's common stock, one quarter of which will vest on January 7, 2023, with the remaining three quarters vesting in equal monthly installments through January 7, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| April 27, 2021 Filed Apr 27, 2021 17:04 UTC | Rain Oncology Inc. RAIN · Entity 94695 | ConversionSeries A Preferred Stock · Derivative | 5,327 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-017112 · doc4.xml · derivative · entry 2 Doebele Robert · CIK 0001856681 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,932 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-1.0799 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-1.0799 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-1.0799 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| April 27, 2021 Filed Apr 27, 2021 17:04 UTC | Rain Oncology Inc. RAIN · Entity 94695 | ConversionCommon Stock | 4,932 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-017112 · doc4.xml · nonDerivative · entry 1 Doebele Robert · CIK 0001856681 · EVP, Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-1.0799 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.